Harvard Bioscience, Inc.

Harvard Bioscience develops, manufactures, and sells life science technologies, products, and services. Products include syringe pumps, electroporation instruments, amino acid analyzers, spectrophotometers, and precision scientific measuring instrumentation. The company also provides preclinical products for research, drug discovery, and development. These products include telemetry systems, behavioral products, surgical products, and respiratory system solutions. Harvard Bioscience markets its products through sales organizations, websites, and distributors to various industries. The company sells its products under several brands including Harvard Apparatus and BTX. Harvard Bioscience was founded in 1901 and is based in Massachusetts.

Overview

Sector

Medical Instruments & Supplies

Target Price

0.0 USD

Current Price

0.5 USD

Potential

-100%

Strengths

Price to book ratio (0.34) is lower than the sector mean (3.86).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (298.66) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.93%) is significantly lower than the sector mean (8.23%).
EV/EBITDA (372.03) is significantly higher than the sector mean (47.53).
EV/EBIT (100.00) is significantly higher than the sector mean.
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.31%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	374.3
Price/Free Cash Flow'	100.0
ROIC	0.9%
Net Debt/EBITDA	298.7